[go: up one dir, main page]

PE20110023A1 - Composiciones inmunogenicas de antigenos de staphylococcus aureus - Google Patents

Composiciones inmunogenicas de antigenos de staphylococcus aureus

Info

Publication number
PE20110023A1
PE20110023A1 PE2010000420A PE2010000420A PE20110023A1 PE 20110023 A1 PE20110023 A1 PE 20110023A1 PE 2010000420 A PE2010000420 A PE 2010000420A PE 2010000420 A PE2010000420 A PE 2010000420A PE 20110023 A1 PE20110023 A1 PE 20110023A1
Authority
PE
Peru
Prior art keywords
aureus
isolated
polypeptide
staphylococcus aureus
clfb
Prior art date
Application number
PE2010000420A
Other languages
English (en)
Inventor
Annaliesa Anderson
Viliam Pavliak
Kathrin Ute Jansen
Ingrid Lea Dodge
Steven Morris Baker
Jasdeep Singh Nanra
Ellen Murphy
Bruce Arthur Green
Mark Edward Ruppen
Yekaterina Timofeyeva
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PE20110023A1 publication Critical patent/PE20110023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION INMUNOGENICA QUE CONTIENE AL MENOS TRES COMPONENTES DE ENTRE: A) UN POLIPEPTIDO DEL FACTOR AGLUTINANTE A AISLADO DE S. AUREUS (ClfA); B) UN POLIPEPTIDO DEL FACTOR AGLUTINANTE B AISLADO DE S. AUREUS (ClfB), DONDE EL POLIPEPTIDO ClfA O ClfB ES UN FRAGMENTO DE POLIPEPTIDO QUE COMPRENDE LOS DOMINIOS N1, N2 Y N3 DE ENLACE A FIBRINOGENO, LOS CUALES SE ENLAZAN A TRAVES DE UNA SUSTITUCION DE AMINOACIDO DE ALA O SER EN TYR 338, TYR 256, PRO 336, LYS 389, ALA 254 E ILE 387; C) UN POLISACARIDO CAPSULAR DE S. AUREUS AISLADO TIPO 5 O-ACETILADO EN UN 10% A 100%, CONJUGADO A UNA PROTEINA PORTADORA QUE ES EL TOXOIDE CRM197 DE C. DIPHTHERIAE; D) UNA PROTEINA MntC AISLADA DE S. AUREUS QUE PUEDE ESTAR LIPIDADA O NO; E) UN POLISACARIDO CAPSULAR TIPO 8 AISLADO DE S. AUREUS O-ACETILADO EN UN 10% A 100%, CONJUGADO A UNA PROTEINA PORTADORA QUE ES EL TOXOIDE CRM197 DE C. DIPHTHERIAE. SE REFIERE TAMBIEN A UN METODO PARA INDUCIR UNA RESPUESTA INMUNE CONTRA STAPHYLOCOCCUS AUREUS QUE COMPRENDE LA GENERACION DE ANTICUERPOS QUE TIENEN ACTIVIDAD OPSONOFAGOCITICA (OPA) CONTRA S. AUREUS
PE2010000420A 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus PE20110023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21913409P 2009-06-22 2009-06-22

Publications (1)

Publication Number Publication Date
PE20110023A1 true PE20110023A1 (es) 2011-01-31

Family

ID=42542752

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014001322A PE20142188A1 (es) 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus
PE2010000420A PE20110023A1 (es) 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014001322A PE20142188A1 (es) 2009-06-22 2010-06-22 Composiciones inmunogenicas de antigenos de staphylococcus aureus

Country Status (27)

Country Link
US (3) US8568735B2 (es)
EP (2) EP3238742A1 (es)
JP (3) JP5395264B2 (es)
KR (1) KR101486122B1 (es)
CN (2) CN102481352A (es)
AR (2) AR078601A1 (es)
AU (1) AU2010264538B2 (es)
BR (1) BRPI1015567A2 (es)
CA (1) CA2766629C (es)
CO (1) CO6480925A2 (es)
DK (1) DK2445522T3 (es)
ES (1) ES2642076T3 (es)
HU (1) HUE036372T2 (es)
IL (1) IL217084B (es)
MX (2) MX343111B (es)
MY (1) MY169837A (es)
NZ (1) NZ597154A (es)
PE (2) PE20142188A1 (es)
PL (1) PL2445522T3 (es)
PT (1) PT2445522T (es)
RU (1) RU2536981C9 (es)
SA (1) SA110310528B1 (es)
SG (3) SG10201707084SA (es)
SI (1) SI2445522T1 (es)
TW (1) TWI469789B (es)
WO (1) WO2010151544A1 (es)
ZA (1) ZA201200501B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
EP2414387B1 (en) 2009-04-03 2015-12-16 University Of Chicago Compositions and methods related to protein a (spa) variants
EP2445523B1 (en) 2009-06-22 2019-04-17 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 8 capsular polysaccharide conjugate immunogenic compositions
PT2445522T (pt) * 2009-06-22 2017-10-04 Wyeth Llc Composições imunogénicas de antigénios de staphylococcus aureus
TWI502068B (zh) 2009-07-15 2015-10-01 Aimm Therapiutics B V 革蘭氏陽性菌特異性結合的化合物
DK2493498T3 (en) 2009-10-30 2017-05-08 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
CN103826656B (zh) * 2010-12-22 2015-08-26 惠氏有限责任公司 金黄色葡萄球菌抗原的稳定的免疫原性组合物
BR112013020086B1 (pt) * 2011-02-08 2020-12-08 Medimmune, Llc Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina
BR112013030963B1 (pt) 2011-06-01 2020-12-01 Xiamen University proteína de fusão, polinucleotídio, constructo, vetor, célula hospedeira, composição farmacêutica ou vacina, uso da proteína de fusão, método para modificar uma proteína alvo para melhorar sua imunogenicidade e uso do fragmento de crm197 ou um fragmento do mesmo
EP2734229B1 (en) * 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
RU2014112343A (ru) * 2011-09-01 2015-10-10 Новартис Аг Оставы антигенов staphylococcus aureus, содержащие адъюванты
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
US8859740B2 (en) 2012-10-26 2014-10-14 Sorrento Therapeutics Inc. Anti-infective binding proteins that bind AIP2
ES2776179T3 (es) * 2012-11-06 2020-07-29 Medimmune Llc Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
CA2906771A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
BR112015028650A2 (pt) * 2013-05-21 2017-09-19 Arsanis Biosciences Gmbh UM ANTÍGENO ISOLADO PARA LEUCOCIDINA DE S. AUREUS, UM ANTICORPO LIGANTE ESPECÍFICO PARA O ANTÍGENO, E UM COMPLEXO CD11b/CD18 HUMANO PARA UTILIZAÇÃO EM UM MÉTODO ANALÍTICO
GB201310008D0 (en) * 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
CN103412122B (zh) * 2013-08-09 2015-06-24 安徽农业大学 同步检测金葡菌a型和g型肠毒素的基于多表位串联肽的间接竞争elisa方法
CN103951748B (zh) * 2014-04-18 2017-07-11 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌eLtaS蛋白的单克隆中和性抗体E4‑1的制备及其应用
CN103951749B (zh) * 2014-04-18 2017-07-11 中国人民解放军军事医学科学院基础医学研究所 一种抗金黄色葡萄球菌eLtaS蛋白的单克隆中和性抗体E4‑2的制备及其应用
US20170281744A1 (en) * 2014-12-10 2017-10-05 Glaxosmithkline Biologicals Sa Method of treatment
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
US11097000B2 (en) * 2016-10-03 2021-08-24 National Taiwan University Klebsiella pneumoniae capsule polysaccharide vaccines
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN106544432A (zh) * 2016-11-08 2017-03-29 江苏大学 一种金黄色葡萄球菌耐药性和毒力快速检测方法及试剂盒
KR20240169144A (ko) 2017-01-31 2024-12-02 머크 샤프 앤드 돔 엘엘씨 다당류-단백질 접합체 제조 방법
US11305001B2 (en) * 2017-03-28 2022-04-19 The Children's Medical Center Corporation Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof
US10232009B1 (en) * 2017-09-29 2019-03-19 Pro Sunfun Biotech Research And Development Co., Ltd. Peptide for promoting wound healing, its composition and method of using the same
US10774135B2 (en) 2017-12-22 2020-09-15 Sorrento Therapeutics, Inc. Variant antibodies that bind AIP2
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
US11260119B2 (en) * 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP7239509B6 (ja) * 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
JP7643730B2 (ja) 2019-05-14 2025-03-11 ザ・ユニバーシティ・オブ・シカゴ ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物
RU2707922C1 (ru) * 2019-06-27 2019-12-02 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Рекомбинантная плазмидная ДНК pQE-30_P36GP12_GP57, обеспечивающая синтез рекомбинантного белка P36GP12 в клетках Escherichia coli, штамм бактерий Escherichia coli - продуцент рекомбинантного белка P36GP12, рекомбинантный белок P36GP12, обладающий способностью связывать липополисахариды Escherichia coli
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN111072775B (zh) * 2019-12-26 2021-08-20 成都欧林生物科技股份有限公司 抗MntC蛋白抗体及其应用和包含其的试剂盒
CN111138551A (zh) * 2020-01-15 2020-05-12 黑龙江八一农垦大学 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用
WO2021165847A1 (en) 2020-02-21 2021-08-26 Pfizer Inc. Purification of saccharides
JP2023546446A (ja) 2020-10-22 2023-11-02 ファイザー・インク 細菌多糖を精製する方法
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2024002331A1 (en) * 2022-06-30 2024-01-04 Shanghai Yuguan Biotech Co., Ltd. A live bacteria strain with reduced capsules
CN118146362B (zh) * 2024-03-15 2025-02-07 重庆原伦生物科技有限公司 一种抗金黄色葡萄球菌锰离子转运蛋白c的抗体及其应用

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134214A (en) 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
SE454403B (sv) 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
IL78775A (en) 1985-05-15 1992-06-21 Biotech Australia Pty Ltd Oral vaccines
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
CA2047031A1 (en) 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
NZ239643A (en) 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5635348A (en) 1990-10-05 1997-06-03 Hoffmann-La Roche Inc. Method and probes for identifying bacteria found in blood
ES2198405T3 (es) 1991-11-22 2004-02-01 Nabi Biopharmaceuticals Antigenos de superficie de tipo i asociados a staphylococcus epidermis.
US5980908A (en) 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
EP0635132B2 (en) 1992-03-19 2008-05-14 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies that react with common staphylococcal antigens
DE69434079T2 (de) 1993-03-05 2005-02-24 Wyeth Holdings Corp. Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin
AU678613B2 (en) 1993-09-22 1997-06-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
WO1996009321A1 (en) 1994-09-21 1996-03-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Broadly reactive opsonic antibodies reactive with common staphylococcal antigens
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US6593114B1 (en) 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
JP4235262B2 (ja) 1997-06-12 2009-03-11 シンエツ・バイオ，インコーポレイテッド 組換え細菌宿主における非生来細菌性エキソ多糖の産生
AU8407298A (en) 1997-07-17 1999-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hexadecasaccharide-protein conjugate vaccine for (shigella dysenteriae) type
US6380370B1 (en) 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
US7060458B1 (en) 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
AU1537699A (en) 1997-11-26 1999-06-15 Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency Extracellular matrix-binding proteins from (staphylococcus aureus)
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
MXPA01002120A (es) 1998-08-31 2003-03-27 Trinity College Dublin Polipeptidos y polinucleotidos de estafilococo negativo a coagulasa.
AU771426B2 (en) 1998-08-31 2004-03-18 Inhibitex, Inc. Multicomponent vaccines
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US6146902A (en) 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
EP1035137A1 (en) 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
HU229968B1 (hu) 1999-03-19 2015-03-30 Smithkline Beecham Biologicals S.A Sztreptokokkusz oltóanyag
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
EP1173485A1 (en) 1999-05-03 2002-01-23 Medarex, Inc. Human antibodies to staphylococcus aureus
US7384640B1 (en) 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
CA2723664A1 (en) 2000-03-22 2001-09-27 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2001281812B2 (en) 2000-06-08 2005-04-07 Valneva Austria Gmbh Immunostimulatory oligodeoxynucleotides
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
DK1377314T3 (da) 2001-01-26 2011-12-12 Inhibitex Inc Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner
EP1404279A4 (en) 2001-06-07 2007-08-08 Wyeth Corp MUTANT FORMS OF CHOLERA HOLOTOXIN AS ADJUVANT
CN1297316C (zh) 2001-06-07 2007-01-31 惠氏控股有限公司 作为佐剂的霍乱全毒素的突变体形式
CA2450939C (en) 2001-06-15 2012-11-06 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA2351018A1 (en) 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
WO2003011899A2 (en) 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
FR2828404B1 (fr) 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
CA2478029A1 (en) 2002-03-05 2003-09-18 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
TW200306314A (en) 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
GB0220198D0 (en) 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
CN100351260C (zh) 2002-11-12 2007-11-28 布赖汉姆妇女医院 葡萄球菌感染的多糖疫苗
JP4078417B2 (ja) 2003-03-04 2008-04-23 独立行政法人産業技術総合研究所 好熱菌由来オリゴペプチダーゼ
CN102366630B (zh) 2003-03-07 2015-04-01 惠氏控股公司 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
DE602004024179D1 (de) 2003-03-31 2009-12-31 Intercell Ag Staphylococcus epidermidis antigene
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN1984676A (zh) 2003-12-17 2007-06-20 惠氏公司 免疫原性肽载体结合物及其生产方法
US7537766B2 (en) 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
GB0421079D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Immunogenic composition
JP2008513406A (ja) * 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
AU2005333603A1 (en) 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of Staphylococcus epidermidis polypeptide antigens
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
GB0606416D0 (en) * 2006-03-30 2006-05-10 Glaxosmithkline Biolog Sa Immunogenic composition
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
BRPI0710210A2 (pt) * 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
US20070253985A1 (en) 2006-04-26 2007-11-01 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
HUE039169T2 (hu) 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
ES2960604T3 (es) 2008-01-31 2024-03-05 The Provost Fellows Found Scholars & The Other Members Of Board Of The College Of The Holy & Undiv T Tratamiento de infecciones microbianas
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2445523B1 (en) 2009-06-22 2019-04-17 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 8 capsular polysaccharide conjugate immunogenic compositions
PT2445522T (pt) 2009-06-22 2017-10-04 Wyeth Llc Composições imunogénicas de antigénios de staphylococcus aureus
US9353160B2 (en) 2009-07-16 2016-05-31 Glaxosmithkline Biologicals S.A. Method of prophlactically treating infection using a recombinant fibrinogen binding protein clumping factor A (ClfA) or fragment thereof
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
DK2493498T3 (en) 2009-10-30 2017-05-08 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 and type 8 capsule saccharides
CN103826656B (zh) 2010-12-22 2015-08-26 惠氏有限责任公司 金黄色葡萄球菌抗原的稳定的免疫原性组合物

Also Published As

Publication number Publication date
RU2536981C9 (ru) 2015-05-10
IL217084A0 (en) 2012-02-29
JP5395264B2 (ja) 2014-01-22
IL217084B (en) 2018-11-29
ZA201200501B (en) 2012-10-31
DK2445522T3 (en) 2017-09-25
JP2016034956A (ja) 2016-03-17
US9114105B2 (en) 2015-08-25
JP5870052B2 (ja) 2016-02-24
NZ597154A (en) 2013-10-25
JP6067806B2 (ja) 2017-01-25
EP2445522B1 (en) 2017-08-09
KR101486122B1 (ko) 2015-01-23
EP2445522A1 (en) 2012-05-02
JP2013151501A (ja) 2013-08-08
HUE036372T2 (hu) 2018-07-30
AR119682A2 (es) 2022-01-05
CN102481352A (zh) 2012-05-30
MY169837A (en) 2019-05-16
PL2445522T3 (pl) 2018-01-31
KR20120046189A (ko) 2012-05-09
SG176837A1 (en) 2012-01-30
CA2766629C (en) 2020-03-24
AU2010264538A1 (en) 2012-01-19
PE20142188A1 (es) 2014-12-29
JP2012530786A (ja) 2012-12-06
TW201103557A (en) 2011-02-01
CN107096020A (zh) 2017-08-29
RU2536981C2 (ru) 2014-12-27
SG10201707084SA (en) 2017-10-30
CO6480925A2 (es) 2012-07-16
BRPI1015567A2 (pt) 2021-08-31
SG10201406520YA (en) 2014-11-27
AU2010264538B2 (en) 2013-10-03
SA110310528B1 (ar) 2014-07-02
SI2445522T1 (sl) 2017-10-30
US20120107327A1 (en) 2012-05-03
MX2012000044A (es) 2012-01-30
MX343111B (es) 2016-10-25
US20140017271A1 (en) 2014-01-16
PT2445522T (pt) 2017-10-04
US8568735B2 (en) 2013-10-29
EP3238742A1 (en) 2017-11-01
WO2010151544A1 (en) 2010-12-29
US8889145B2 (en) 2014-11-18
US20150132336A1 (en) 2015-05-14
AR078601A1 (es) 2011-11-23
ES2642076T3 (es) 2017-11-15
TWI469789B (zh) 2015-01-21
RU2011151781A (ru) 2013-07-27
CA2766629A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
PE20110023A1 (es) Composiciones inmunogenicas de antigenos de staphylococcus aureus
AR125327A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
CO6231039A2 (es) Composiciones que comprenden anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CY1121023T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
CO6341637A2 (es) \\\\\\\"composiciones y metodos novedosos\\\\\\\"
NO20083793L (no) Antistoffer mot amyloid-beta peptid
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
PE20110065A1 (es) Composiciones y metodos para preparar composiciones inmunogenicas de conjugado de polisacarido capsular de staphylococcus aureus serotipos 5 y 8
BRPI0515316A (pt) compostos de imidazoquinolina
CO6382140A2 (es) Composiciones de vacuna que comprenden una proteina de enlace del factor h mutada
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
PE20070499A1 (es) Composicion inmunogenica
AR057614A1 (es) Composiciones y metodos para producir moleculas de union con antigeno hibridas y usos de las mismas
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
EA201001639A1 (ru) Композиции и способы их получения и применения
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
PE20140173A1 (es) Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
EA200970131A1 (ru) Миметические антитела для glp-1 человека, композиции, способы и применения
AR092897A1 (es) Composiciones inmunogenicas
SI2542257T1 (en) Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI)
AR081809A1 (es) Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas

Legal Events

Date Code Title Description
FG Grant, registration